Short answer
Celcuity Inc. (CELC) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$73M
- −67.4% YoY · +7.0% QoQ
- EPS (diluted)
- −$1.33
- −46.2% YoY · +7.6% QoQ
Source: XBRL data from the Celcuity Inc. (CELC) Q3 2026 10-Q on SEC EDGAR. USD.
Celcuity Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly product revenue $0, unchanged YoY, as REVTORPYK shipments began September 30, 2026
- Net loss $73.3M vs $43.8M YoY, operating loss $77.3M vs $42.8M
- Worst cost trend: SG&A $39.8M, up 220% YoY, driven by commercialization spending
- Cash, equivalents and short-term investments $642.7M; operating cash use $176.7M through nine months
- Cash runway expected through 2029, with commercialization and clinical-development spending increasing
Risk Factors
- New regulatory risk: August 2026 sNDA for PIK3CA-mutated patients may face delay, rejection, narrower labeling, or additional data requirements
- Regulatory and compliance risk: FDA noncompliance could trigger recalls, approval withdrawal, fines, injunctions, or criminal penalties
- Market risk: REVTORPYK faces competition from alpelisib, capivasertib, everolimus, and endocrine regimens
- Pricing and reimbursement risk: Proposed Medicare MFN rebate models could begin January 1, 2027
- Intellectual-property risk: Generic competition could follow patent challenges and substantially reduce REVTORPYK revenue
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Celcuity Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.